Specific correction of a splice defect in brain by nutritional supplementation

Area of Science:

• Molecular Biology
• Genetics
• Neuroscience

Background:

• mRNA splicing defects are implicated in 20-30% of human genetic diseases.
• Familial dysautonomia (FD) is a neurodegenerative disorder caused by a specific mutation in the IKBKAP gene, leading to exon skipping and reduced IKAP protein.
• The plasticity of mRNA splicing presents therapeutic opportunities for genetic disorders.

Purpose of the Study:

• To evaluate the efficacy of kinetin in correcting IKBKAP splicing defects in a transgenic mouse model of Familial Dysautonomia (FD).
• To assess the impact of kinetin treatment on wild-type IKBKAP mRNA and IKAP protein levels in various tissues, including the brain.

Main Methods:

• Generation of transgenic mouse lines carrying a human IKBKAP bacterial artificial chromosome (BAC) with the FD-causing splice mutation.
• Administration of kinetin to FD BAC transgenic mice.
• Analysis of IKBKAP splicing patterns, wild-type mRNA levels, and IKAP protein expression across major tissues.

Main Results:

• Kinetin treatment successfully corrected IKBKAP splicing in all major tissues of the FD BAC transgenic mice, including the brain.
• Significant increases in wild-type IKBKAP mRNA and IKAP protein were observed in kinetin-treated mice compared to controls.
• The results demonstrate kinetin's ability to restore normal splicing and protein production in vivo.

Conclusions:

• Kinetin effectively corrects the tissue-specific aberrant splicing of IKBKAP in a mouse model of Familial Dysautonomia.
• This study provides strong evidence for kinetin as a potential therapeutic agent for FD by restoring functional protein levels.
• Kinetin holds promise for treating FD and other genetic disorders caused by similar mRNA splicing defects.